Press release
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
Data shared during the 2023 Fall Clinical Dermatology Conference for PAs & NPs® FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq:
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nData shared during the 2023 Fall Clinical Dermatology Conference for PAs & NPs®\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ability of the DecisionDx®-SCC test to identify cutaneous squamous cell carcinoma (cSCC) tumors at a biologically high risk of metastasis in a subset of patients considered to be at a low risk of metastasis by traditional staging (i.e., patients with T1 tumors under the American Joint Committee on Cancer Eighth Edition (AJCC8) and Brigham and Women’s Hospital (BWH) staging systems). The data was shared in a poster, titled “The 40-gene expression profile (40-GEP) test allows for an improved prognostication of the likelihood of metastasis in patients with T1 cutaneous squamous cell carcinoma (cSCC) with high-risk factors,” during the recent 2023 Fall Clinical Dermatology Conference for PAs & NPs®.\n\n\n“Traditional staging, which includes solely tumor characteristics, only tells part of the story and leaves out a very critical piece of the plot, the biology of an individual patient’s tumor, which can provide greater insight into each patient’s unique metastatic propensity,” said Ally-Khan Somani, M.D., Ph.D., board-certified dermatologist, Mohs micrographic surgeon and director of Dermatologic Surgery & Cutaneous Oncology Division at the Indiana University School of Medicine in Indianapolis. “By estimating a cSCC patient’s personal risk of metastasis, the DecisionDx-SCC test has proven to elevate the narrative, which can lead to more informed, pertinent risk-aligned treatment decisions that can help improve outcomes.”\n\n\nIn the study, the DecisionDx-SCC test was able to significantly stratify three-year metastasis free survival rates within the AJCC8 and BWH T1 populations of the cSCC cohort. Approximately 70% of the AJCC8- and BWH-staged T1 tumors that metastasized were identified as being biologically high-risk by the DecisionDx-SCC test. This data supports the ability of the test to improve risk assessments based on staging alone, enabling clinicians and patients to make more risk-appropriate surveillance and treatment decisions.\n\n\nCastle’s poster will be published in SKIN, The Journal of Cutaneous Medicine® (www.jofskin.org), and may also ...